Meibomian Gland Expression (MGX) held a 43.67% share of the dry eye treatment devices market in 2025, reflecting its established role in routine clinical management of meibomian gland dysfunction-related dry eye. its position is maintained through broad familiarity among eye care providers, straightforward integration into treatment workflows, and its direct therapeutic relevance for patients requiring gland clearance as part of standard dry eye care. In the dry eye treatment devices market, MGX continues to benefit from its practical use in structured in-clinic treatment pathways where clinicians prioritize proven, repeatable intervention approaches.

Combination (MGX+IPL) is emerging as the fastest-growing technology in the dry eye treatment devices market because providers are increasingly looking for more comprehensive in-office treatment approaches that address multiple contributors to dry eye within a more consolidated care model. Compared with standalone alternatives, the combination of MGX and IPL is gaining momentum as clinical settings seek treatment options that can fit evolving expectations for broader procedural effectiveness and more integrated management of complex dry eye presentations. Its growth is being reinforced through this shift toward combined therapeutic protocols rather than single-modality intervention.

End-use Segment Analysis: Hospitals (Largest Segment) vs Ophthalmic Clinics (Fastest-Growing Segment)

Hospitals accounted for the largest share of the dry eye treatment devices market in 2025, reinforced through their ability to manage a broad patient base and incorporate dry eye treatment within wider ophthalmic service delivery. Their leading share reflects established infrastructure, access to specialized equipment, and the operational capacity to offer device-based care as part of comprehensive eye treatment pathways. In the dry eye treatment devices market, hospitals maintain leadership because patients with more involved ocular evaluations and procedural needs are often funneled through these settings where multidisciplinary support and treatment continuity are readily available.

Ophthalmic Clinics represent the fastest-growing end-use segment in the dry eye treatment devices market as care delivery increasingly shifts toward specialized outpatient environments focused on targeted eye disorders. Their momentum is tied to a more dedicated clinical setup for dry eye assessment and treatment, which allows faster adoption of device-based procedures aligned with growing patient demand for focused and accessible eye care services. Relative to broader healthcare settings, ophthalmic clinics are gaining traction because their specialization supports more streamlined dry eye treatment workflows and closer alignment with routine follow-up care.